James S Goydos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2036263/publications.pdf

Version: 2024-02-01

78 papers	4,779 citations	101543 36 h-index	95266 68 g-index
80 all docs	80 docs citations	80 times ranked	6292 citing authors

#	Article	IF	Citations
1	MDM4 is a key therapeutic target in cutaneous melanoma. Nature Medicine, 2012, 18, 1239-1247.	30.7	266
2	Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nature Genetics, 2003, 34, 108-112.	21.4	260
3	Rewired ERK-JNK Signaling Pathways in Melanoma. Cancer Cell, 2007, 11, 447-460.	16.8	260
4	A Phase I Trial of a Synthetic Mucin Peptide Vaccine. Journal of Surgical Research, 1996, 63, 298-304.	1.6	243
5	Lessons learned from the Sunbelt Melanoma Trial. Journal of Surgical Oncology, 2004, 86, 212-223.	1.7	209
6	Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma. Clinical Cancer Research, 2008, 14, 8302-8307.	7.0	193
7	The Regulation of miRNA-211 Expression and Its Role in Melanoma Cell Invasiveness. PLoS ONE, 2010, 5, e13779.	2.5	184
8	Metabotropic Glutamate Receptor 1 and Glutamate Signaling in Human Melanoma. Cancer Research, 2007, 67, 2298-2305.	0.9	166
9	Melanoma Patients with Positive Sentinel Nodes Who Did Not Undergo Completion Lymphadenectomy: A Multi-Institutional Study. Annals of Surgical Oncology, 2006, 13, 809-816.	1.5	161
10	Gender-Related Differences in Outcome for Melanoma Patients. Annals of Surgery, 2006, 243, 693-700.	4.2	155
11	GLI2-Mediated Melanoma Invasion and Metastasis. Journal of the National Cancer Institute, 2010, 102, 1148-1159.	6.3	149
12	Store-Operated Ca2+ Entry (SOCE) Regulates Melanoma Proliferation and Cell Migration. PLoS ONE, 2014, 9, e89292.	2.5	130
13	Prospective Multi-Institutional Study of Reverse Transcriptase Polymerase Chain Reaction for Molecular Staging of Melanoma. Journal of Clinical Oncology, 2006, 24, 2849-2857.	1.6	127
14	Marked Elevation of Serum Interleukin-6 in Patients With Cholangiocarcinoma. Annals of Surgery, 1998, 227, 398-404.	4.2	126
15	Factors Associated with False-Negative Sentinel Lymph Node Biopsy in Melanoma Patients. Annals of Surgical Oncology, 2010, 17, 709-717.	1.5	93
16	A Phase 0 Trial of Riluzole in Patients with Resectable Stage III and IV Melanoma. Clinical Cancer Research, 2009, 15, 3896-3902.	7.0	92
17	The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and -independent pathways. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16713-16718.	7.1	90
18	Detection of B-RAF and N-RAS mutations in human melanoma. Journal of the American College of Surgeons, 2005, 200, 362-370.	0.5	82

#	Article	IF	Citations
19	Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. Journal of Clinical Oncology, 2016, 34, 1079-1086.	1.6	66
20	Exchange Protein Directly Activated by Cyclic AMP Increases Melanoma Cell Migration by a Ca2+-Dependent Mechanism. Cancer Research, 2010, 70, 5607-5617.	0.9	65
21	Minimally invasive staging of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction. Journal of the American College of Surgeons, 1998, 187, 182-188.	0.5	64
22	Differential expression of vascular endothelial growth factorâ€“A isoforms at different stages of melanoma progression. Journal of the American College of Surgeons, 2003, 197, 408-418.	0.5	62
23	Acral Lentiginous Melanoma. Cancer Treatment and Research, 2016, 167, 321-329.	0.5	61
24	Plant Lectin Can Target Receptors Containing Sialic Acid, Exemplified by Podoplanin, to Inhibit Transformed Cell Growth and Migration. PLoS ONE, 2012, 7, e41845.	2.5	61
25	NY-ESO-1 and CTp11 Expression May Correlate with Stage of Progression in Melanoma. Journal of Surgical Research, 2001, 98, 76-80.	1.6	60
26	Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies. Clinical Cancer Research, 2011, 17, 7080-7092.	7.0	58
27	The Glutamate Release Inhibitor Riluzole Decreases Migration, Invasion, and Proliferation of Melanoma Cells. Journal of Investigative Dermatology, 2010, 130, 2240-2249.	0.7	57
28	Patterns of recurrence in patients with melanoma and histologically negative but RT-PCR-positive sentinel lymph nodes. Journal of the American College of Surgeons, 2003, 196, 196-204.	0.5	56
29	Vascular endothelial growth factor C mRNA expression correlates with stage of progression in patients with melanoma. Clinical Cancer Research, 2003, 9, 5962-7.	7.0	49
30	Sun protection and exposure behaviors among Hispanic adults in the United States: differences according to acculturation and among Hispanic subgroups. BMC Public Health, 2012, 12, 985.	2.9	47
31	Linguistic Acculturation and Skin Cancerâ€“Related Behaviors Among Hispanics in the Southern and Western United States. JAMA Dermatology, 2013, 149, 679.	4.1	47
32	Metabotropic Glutamate Receptor-1 Contributes to Progression in Triple Negative Breast Cancer. PLoS ONE, 2014, 9, e81126.	2.5	43
33	Activation of the Glutamate Receptor GRM1 Enhances Angiogenic Signaling to Drive Melanoma Progression. Cancer Research, 2014, 74, 2499-2509.	0.9	43
34	Participation of xCT in melanoma cell proliferation in vitro and tumorigenesis in vivo. Oncogenesis, 2018, 7, 86.	4.9	43
35	A phase <scp>II</scp> trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (<scp>GRM</scp>1) signaling, in patients with advanced melanoma. Pigment Cell and Melanoma Research, 2018, 31, 534-540.	3.3	42
36	AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1). Pigment Cell and Melanoma Research, 2010, 23, 103-111.	3.3	41

#	Article	IF	Citations
37	Skin self-examination behaviors among individuals diagnosed with melanoma. Melanoma Research, 2016, 26, 71-76.	1.2	38
38	Riluzole Enhances Ionizing Radiationâ€“Induced Cytotoxicity in Human Melanoma Cells that Ectopically Express Metabotropic Glutamate Receptor 1 In Vitro and In Vivo. Clinical Cancer Research, 2011, 17, 1807-1814.	7.0	37
39	RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion. Cancer Letters, 2014, 348, 61-70.	7.2	37
40	Extracellular cAMP-dependent protein kinase (ECPKA) in melanoma. Cancer Letters, 2004, 208, 187-191.	7.2	36
41	c-Jun Regulates Phosphoinositide-dependent Kinase 1 Transcription. Journal of Biological Chemistry, 2010, 285, 903-913.	3.4	36
42	Functional Effects of GRM1 Suppression in Human Melanoma Cells. Molecular Cancer Research, 2012, 10, 1440-1450.	3.4	36
43	Use of Sentinel Node Lymphoscintigraphy in Malignant Melanoma. Radiographics, 1999, 19, 343-356.	3.3	31
44	Skin cancer surveillance behaviors among US Hispanic adults. Journal of the American Academy of Dermatology, 2013, 68, 576-584.	1.2	31
45	Psychosocial correlates of sun protection behaviors among U.S. Hispanic adults. Journal of Behavioral Medicine, 2014, 37, 1082-1090.	2.1	31
46	Lymphatic mapping and intraoperative lymphoscintigraphy for identifying the sentinel node in penile tumors. Urology, 2000, 55, 582-585.	1.0	30
47	Epac1 promotes melanoma metastasis via modification of heparan sulfate. Pigment Cell and Melanoma Research, 2011, 24, 680-687.	3.3	30
48	Epac1 increases migration of endothelial cells and melanoma cells via <scp>FGF</scp>2â€mediated paracrine signaling. Pigment Cell and Melanoma Research, 2014, 27, 611-620.	3.3	29
49	Factors Associated With Improved Survival Among Young Adult Melanoma Patients Despite a Greater Incidence of Sentinel Lymph Node Metastasis. Journal of Surgical Research, 2007, 143, 164-168.	1.6	25
50	Disruption of <scp>GRM</scp>1â€mediated signalling using riluzole results in <scp>DNA</scp> damage in melanoma cells. Pigment Cell and Melanoma Research, 2014, 27, 263-274.	3.3	25
51	The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma. Oncotarget, 2016, 7, 29689-29707.	1.8	24
52	Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factorâ€Î²â€mediated growth inhibition. Pigment Cell and Melanoma Research, 2011, 24, 512-524.	3.3	23
53	Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression. Translational Oncology, 2015, 8, 1-9.	3.7	23
54	Tumor cell and circulating markers in melanoma: Diagnosis, prognosis, and management. Current Oncology Reports, 2005, 7, 377-382.	4.0	22

#	Article	IF	Citations
55	Effect of Multipleâ€“Nodal Basin Drainage on Cutaneous Melanoma. Archives of Surgery, 2008, 143, 632.	2.2	22
56	Surveillance after surgical treatment of melanoma: Futility of routine chest radiography. Surgery, 2010, 148, 711-717.	1.9	22
57	The EphB4 receptor promotes the growth of melanoma cells expressing the ephrinâ€B2 ligand. Pigment Cell and Melanoma Research, 2010, 23, 684-687.	3.3	22
58	Occupational sunscreen use among US Hispanic outdoor workers. BMC Research Notes, 2015, 8, 578.	1.4	21
59	Exosomes released by metabotropic glutamate receptor 1 (GRM1) expressing melanoma cells increase cell migration and invasiveness. Oncotarget, 2018, 9, 1187-1199.	1.8	20
60	Molecular analysis of melanoma-induced sentinel lymph node immune dysfunction. Cancer Immunology, Immunotherapy, 2011, 60, 685-692.	4.2	18
61	Gî²î³ subunits inhibit Epac-induced melanoma cell migration. BMC Cancer, 2011, 11, 256.	2.6	17
62	Randomized controlled trial of the mySmartSkin web-based intervention to promote skin self-examination and sun protection behaviors among individuals diagnosed with melanoma: study design and baseline characteristics. Contemporary Clinical Trials, 2019, 83, 117-127.	1.8	17
63	Skin Cancer Screening Among Hispanic Adults in the United States: Results From the 2010 National Health Interview Survey. Archives of Dermatology, 2012, 148, 861-3.	1.4	16
64	Riluzole is a radioâ€sensitizing agent in an in vivo model of brain metastasis derived from <scp>GRM</scp>1 expressing human melanoma cells. Pigment Cell and Melanoma Research, 2015, 28, 105-109.	3.3	16
65	Sentinel Lymph Node Mapping in Melanoma of the Ear. Annals of Plastic Surgery, 1998, 40, 506-509.	0.9	15
66	Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulinâ€like growth factor 1 receptor. Pigment Cell and Melanoma Research, 2014, 27, 621-629.	3.3	14
67	Non-Canonical Smads Phosphorylation Induced by the Glutamate Release Inhibitor, Riluzole, through GSK3 Activation in Melanoma. PLoS ONE, 2012, 7, e47312.	2.5	14
68	Interdigitating Dendritic Cell Sarcoma Presenting in the Skin: Diagnosis and the Role of Surgical Resection, Chemotherapy and Radiotherapy in Management. Rare Tumors, 2014, 6, 135-137.	0.6	13
69	Parent and Child Characteristics Associated with Child Sunburn and Sun Protection Among U.S. Hispanics. Pediatric Dermatology, 2017, 34, 315-321.	0.9	11
70	Facebook Intervention for Young-Onset Melanoma Patients and Their Family Members: Pilot and Feasibility Study. JMIR Dermatology, 2018, 1, e3.	0.7	10
71	Activation of Grm1 expression by mutated BRaf (V600E) in vitro and in vivo. Oncotarget, 2018, 9, 5861-5875.	1.8	5
72	Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development. Pharmaceuticals, 2010, 3, 2821-2837.	3.8	4

#	Article	IF	Citations
73	Who Should Be Offered a Sentinel Node Biopsy for Melanoma Less Than 1 mm in Thickness?. Journal of Clinical Oncology, 2013, 31, 4385-4386.	1.6	4
74	A Molecular Technique Useful in the Detection of Occult Metastases in Patients with Melanoma: RT-PCR Analysis of Sentinel Lymph Nodes and Peripheral Blood. , 2001, 61, 301-320.		1
75	Receptivity to Internet-Delivered Interventions to Promote Skin Self-examination and Sun Protection Behaviors in Patients With Melanoma. JAMA Dermatology, 2016, 152, 213.	4.1	1
76	A phase I trial of riluzole and sorafenib in patients with advanced solid tumors and melanoma.. Journal of Clinical Oncology, 2012, 30, TPS3112-TPS3112.	1.6	1
77	Abstract LB-244: A phase 0 trial of riluzole in patients with resectable stage III or IV melanoma.. , 2008, , .		0
78	Understanding Melanocyte Transformation â€“ A Work in Progress. , 0, , .		0